Diabetes, Obesity & Metabolism最新文献

{"title":"Cardiometabolic diseases and dynamic transitions of neuropsychiatric disorders: A longitudinal trajectory analysis.","authors":"Jiang Li, Xiaoqin Xu, Ying Sun, Yuefeng Yu, Yanqi Fu, Xiao Tan, Liqun He, Ningjian Wang, Yingli Lu, Bin Wang","doi":"10.1111/dom.16614","DOIUrl":"https://doi.org/10.1111/dom.16614","url":null,"abstract":"<p><strong>Background: </strong>The associations of cardiometabolic diseases (CMDs) on the incidence of neurological and psychiatric disorders (NPDs) and progression to neuropsychiatric multimorbidity (NPM) and subsequent death are unclear. We aimed to evaluate the associations between CMDs and dynamic transitions of NPDs.</p><p><strong>Materials and methods: </strong>This prospective cohort study included 402 950 participants from the UK Biobank. NPM was defined as the coexistence of at least two NPDs (dementia, Parkinson disease, anxiety, depression and sleep disorders). A multi-state model was used to explore the association between CMDs (type 2 diabetes, hypertension, ischaemic heart disease and stroke) and the progression trajectory of NPDs.</p><p><strong>Results: </strong>During a median follow-up of 14.1 years, 43 359 participants developed at least one NPD, 9087 developed NPM and 31 307 died. CMDs were significantly associated with different stages of NPD progression. The hazard ratios (95% confidence intervals) per additional CMD were 1.28 (1.26, 1.29) and 1.07 (1.04, 1.10) for transitions from healthy to first neuropsychiatric disease (FNPD), and from FNPD to NPM, and 1.38 (1.36, 1.40), 1.19 (1.16, 1.23) and 1.19 (1.13, 1.25) for death from healthy, FNPD and NPM respectively. When dividing FNPD into individual NPDs, the associations of single and combined CMDs with NPD transitions varied depending on disease types and specific combinations of CMDs, even within the same transition stage. Results from the China Health and Retirement Longitudinal Study cohort confirmed the associations between CMDs and NPDs.</p><p><strong>Conclusion: </strong>CMDs could play important roles in basically all transitions of NPD progression, highlighting the significance of CMD management for the prevention and control of NPDs.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to GLP-1 receptor agonists and SGLT2 inhibitors by out-of-pocket spending among Medicare beneficiaries with diabetes.","authors":"Nicklas S Klepser, Ellerie S Weber, Lihua Li, Kirsten E Fleischmann, Umesh Masharani, Meyeon Park, Wendy B Max, Joseph Yeboah, M G Myriam Hunink, Bart S Ferket","doi":"10.1111/dom.16619","DOIUrl":"https://doi.org/10.1111/dom.16619","url":null,"abstract":"<p><strong>Aims: </strong>To assess associations between out-of-pocket (OOP) expenditures and adherence to glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) among low-income Medicare beneficiaries with diabetes.</p><p><strong>Materials and methods: </strong>We analysed Medicare Current Beneficiary Survey two-year longitudinal data (2016-2021) on beneficiaries with diabetes using GLP-1RAs (N = 168; weighted = 2 187 500) or SGLT2i (N = 139; weighted = 1 741 910) in year one (baseline). Among these, N = 97 (weighted = 1 117 637) GLP-1RA and N = 73 (weighted = 785 301) SGLT2i users had an income below 200% of the Federal Poverty Level (low-income). Survey-weighted generalized Poisson regression assessed the association between baseline cumulative OOP drug expenses and year two adherence, defined as proportion of days covered (PDC). We repeated analyses in participants with higher income and using dual (Medicare/Medicaid) enrolment as a proxy for full coverage in low income.</p><p><strong>Results: </strong>Year-two PDC was 65.2% (95% CI: 57.9%-72.6%) for low-income GLP-1RA users and 65.4% (95% CI: 58.3%-72.5%) for low-income SGLT2i users. We did not observe a significant association between OOP costs (mean: $253; range: $0-$4699) and adherence in low-income GLP-1RA users. For low-income SGLT2i users, higher OOP costs (mean: $204; $0-$2649) were associated with lower adherence: adjusted adherence ratio 0.959 (95% CI: 0.932-0.987) per $100 increase. Dual Medicare-Medicaid coverage was associated with increased adherence: adjusted adherence ratio 1.580 (95% CI: 1.061-2.352). For high-income GLP-1RA users, higher OOP expenditures were associated with increased adherence in the highest income range.</p><p><strong>Conclusions: </strong>OOP costs for GLP-1RAs and SGLT2i are substantial, potentially posing a particular burden for low-income Medicare beneficiaries. Policy changes may reduce this burden, although adherence improvements appear limited to beneficiaries using SGLT2i.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.","authors":"Hannah Wallace, James Wick, Brendon L Neuen, Luke Buizen, Sunil V Badve, John Chalmers, Juliana de Oliveira Costa, Michael O Falster, Jeffrey T Ha, Meg J Jardine, Daniel Bekele Ketema, Jialing Lin, Craig Nelson, Sallie-Anne Pearson, David Peiris, Anthony Rodgers, Takaya Sasaki, Mark Woodward, Martin Gallagher, Sradha S Kotwal, Paul Ronksley, Min Jun","doi":"10.1111/dom.16608","DOIUrl":"https://doi.org/10.1111/dom.16608","url":null,"abstract":"<p><strong>Aims: </strong>Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have cardio-kidney-metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1-RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care.</p><p><strong>Materials and methods: </strong>We conducted a retrospective, cohort study of adults with T2DM who attended primary care practices participating in MedicineInsight. The outcome of interest was the percentage of patients with CKD who received ≥1 prescription for an SGLT2 inhibitor or a GLP1-RA (assessed separately) compared to those without CKD during 2020-2021. We also assessed prescriptions in a sub-population of CKD patients who met trial inclusion criteria: SGLT2 inhibitor (estimated glomerular filtration rate [eGFR] ≥20 mL/min/1.73m² and urine albumin-creatinine ratio [UACR] ≥22.6 mg/mmol) and GLP1-RA (eGFR ≥50 to <75 mL/min/1.73m² and UACR >33.9 to <565 mg/mmol, or eGFR ≥25 to <50 mL/min/1.73m² and UACR >11.3 to <565 mg/mmol).</p><p><strong>Results: </strong>Of 114 499 adults with T2DM, 36 840 (32.1%) also had CKD. SGLT2 inhibitors were prescribed in 13.6% of patients without CKD, 14.4% of patients with CKD and 17.8% of patients meeting the trial target population definition. Across these groups, GLP1-RA were prescribed in 8.8%, 10.1% and 11.3% of patients, respectively. More advanced CKD stage and severely increased albuminuria were associated with a lower likelihood of SGLT2 inhibitor or GLP1-RA being prescribed.</p><p><strong>Conclusion: </strong>We observed low rates of SGLT2 inhibitor and GLP1-RA prescriptions in patients with T2DM irrespective of CKD status. Strategies are needed to improve prescription rates, with a particular focus on patients with high kidney and cardiovascular risk.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to four dietary indices and the risk of all-cause and cause-specific dementia: Findings from the UK Biobank study.","authors":"Fernanda Carrasco-Marín, Solange Parra-Soto, Marion Guerrero-Wyss, Carolina Araya-Bastias, Jirapitcha Boonpor, Carla Villagrán-Cerro, Fanny Petermann-Rocha, Oliver M Shannon, John C Mathers, Katherine M Livingstone, Sara Dingle, Sofía Gálvez-Tejeda, Ana Hernández-Peregrina, Nishka Pranay, Guillermo Molina-Recio, Jill Pell, Frederick Ho, Carlos Celis-Morales, Rafael Molina-Luque","doi":"10.1111/dom.16609","DOIUrl":"https://doi.org/10.1111/dom.16609","url":null,"abstract":"<p><strong>Aims: </strong>Despite several modifiable risk factors for dementia being identified, diet is often excluded from consideration due to insufficient evidence. Although various healthy dietary indices have been associated with improved health outcomes, their link to dementia risk remains unclear. This study investigates the association between four dietary indices and dementia risk among UK Biobank participants.</p><p><strong>Materials and methods: </strong>This study utilized data from the UK Biobank cohort. Dietary intake was self-reported using repeated 24-h recalls (up to five occasions), averaged for analysis. Adherence to a healthy diet was assessed using four dietary indices: the Recommended Food Score (RFS), Healthy Diet Indicator (HDI), Mediterranean Diet Score (MDS) and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) score. The primary outcome was incident all-cause dementia, Alzheimer disease, vascular dementia, and non-vascular dementia extracted from hospital and primary care records using ICD-10 codes. Censored Cox proportional hazards models were used to estimate the risk of developing dementia and reported as hazard ratios (HRs) with their 95% confidence interval (CI). Analyses were adjusted for age, sex, education and various lifestyle and health-related factors.</p><p><strong>Results: </strong>The analysis included 121 521 participants (mean age: 55.7 years; 53.5% women), followed for a median of 10.9 years. During follow-up, 621 participants developed dementia. Compared with individuals with the lowest dietary adherence (Quartile 1), those in the highest adherence group (Quartile 4) showed a lower risk of all-cause dementia for MDS (HR: 0.53; 95% CI: 0.45-0.63), MIND (HR: 0.61; 95% CI: 0.48-0.78), and RFS (HR: 0.66; 95% CI: 0.53-0.85). Similar associations were observed for Alzheimer disease and MDS (HR: 0.55; 95% CI: 0.46-0.67), RFS (HR: 0.61; 95% CI: 0.47-0.80), and MIND (HR: 0.66; 95% CI: 0.51-0.87). For vascular dementia, only MDS (HR: 0.46; 95% CI: 0.31-0.68) and MIND (HR: 0.68; 95% CI: 0.40-0.97) showed a lower risk. These associations remained in a 5-year landmark analysis. No associations were observed for HDI with any dementia outcome. Our findings indicate that higher adherence to specific dietary patterns, particularly the Mediterranean, RFS and MIND diet, is associated with a lower risk of dementia.</p><p><strong>Conclusions: </strong>The Mediterranean Diet demonstrated the strongest association. These results highlight the potential of healthy dietary patterns to improve brain health in older adults.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could continuous subcutaneous glucose sensors (CGMS) be repurposed to diagnose diabetes in equivocal or challenging cases?","authors":"Martin B Whyte, Adrian H Heald","doi":"10.1111/dom.16624","DOIUrl":"https://doi.org/10.1111/dom.16624","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers.","authors":"Junliang Pu, Yurui Huang, Lei Wan, Mingxue Zhu, Huili Wei, Hong Gao, Liping Zhong, Chengyong Tang, Junfang Xu","doi":"10.1111/dom.16610","DOIUrl":"https://doi.org/10.1111/dom.16610","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single oral doses of HDM1002 in healthy adult participants.</p><p><strong>Materials and methods: </strong>This was a first-in-human, randomized, double-blind, placebo-controlled, 2-part study. Healthy participants aged 18 to 55 years with a body mass index (BMI) of 19.0 ~ 32.0 kg/m² were eligible. In the single ascending dose (SAD) part, eligible participants were randomized (8:2) to receive a single oral escalating dose of HDM1002 (10-600 mg) or placebo. In the food effect (FE) part, participants were randomized (7:7) to receive HDM1002 (200 mg) in the fasted and fed states with a two-period, crossover design.</p><p><strong>Results: </strong>A total of 79 participants enrolled and completed the study. The most common adverse events (AEs) were nausea, diarrhoea, vomiting and decreased appetite, which increased in a dose-dependent manner. No serious AEs were reported. C_max and AUC appeared to be dose-proportional from 10 to 600 mg by a power model. The geometric mean t_1/2z ranged from 4.99 to 7.10 h. C_max and AUC of HDM1002 were similar under fed and fasted conditions. HDM1002 significantly lowered postprandial glucose in a dose-dependent manner and maintained the glucose-lowering effect at both 6 and 12 h at 100-600 mg doses.</p><p><strong>Conclusions: </strong>HDM1002 was safe and well tolerated at 10-600 mg. HDM1002 showed linear pharmacokinetics, and a standardized high-fat meal did not impact systemic exposure. These results provide preliminary evidence supporting further clinical development of HDM1002 in individuals with type 2 diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel oral agents in anti-obesity pharmacotherapy: A narrative review.","authors":"Assaf Buch, Roy Eldor, Roy Brown, Joel Zonszein","doi":"10.1111/dom.16618","DOIUrl":"https://doi.org/10.1111/dom.16618","url":null,"abstract":"<p><p>Obesity remains a critical global health issue with profound medical and economic implications. While injectable medications such as semaglutide (Wegovy®) and tirzepatide (Zepbound®) have demonstrated significant efficacy, the development of novel oral anti-obesity agents presents additional therapeutic potential. This narrative review examines recent advances in oral pharmacotherapy for obesity, focusing on mechanisms of action, clinical effectiveness, anticipated benefits and side effects. A systematic search of PubMed, Cochrane Library, Google Scholar and ClinicalTrials.gov identified relevant studies published between January 2023 and June 2025, including randomized controlled trials and clinical investigations of emerging oral agents. We have selected emerging oral compounds, currently undergoing clinical evaluation but not yet approved by the Food and Drug Administration (FDA). These include oral GLP-1 RAs, peptides and small molecules, and non-incretin-based therapies targeting the melanocortin-4 receptor and the endocannabinoid system, among others. Several agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials while also exhibiting favourable safety profiles. Emerging oral therapies could complement or serve as alternatives to approved injectable treatments, particularly for long-term weight management. They may enhance patient access, adherence and satisfaction, thereby broadening the scope of pharmacological interventions in obesity care. Ongoing research is crucial to confirm the long-term safety, effectiveness and clinical role of these agents within comprehensive obesity management strategies. By contextualizing these developments, this review underscores the growing promise of oral pharmacotherapy in addressing the global obesity epidemic.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term associations between metabolic heterogeneity of obesity and cognitive frailty transitions: An ongoing Chinese elderly cohort study.","authors":"Qianfeng Liu, Fuzhi Wang, Li Huang, Xinrui Zhao, Xinru Wei, Xinyue Yu, Yunqin Zheng, Jiaxin Xiao, Jiayan Xue, Yiran Feng, Xingzhao Tian, Shiji Qiu, Zequn Fu, Zhuang Cui, Meilin Zhang, Huan Liu","doi":"10.1111/dom.16613","DOIUrl":"https://doi.org/10.1111/dom.16613","url":null,"abstract":"<p><strong>Aims: </strong>To clarify the association between metabolic heterogeneity of obesity and cognitive frailty (CF) progression and assess the reversibility of CF through early identification of reversible cognitive frailty (RCF).</p><p><strong>Materials and methods: </strong>This ongoing community-based cohort (Tianjin, China; 2023-2024) included 3048 older adults (mean age 68.0 years, 56.9% female) with annual cognitive assessments. Multistate Markov models quantified transition probabilities and hazard ratios between non-CF (NCF), RCF and CF across four metabolic phenotypes of obesity: metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight/obesity (MHOO), and metabolically unhealthy overweight/obesity (MUOO).</p><p><strong>Results: </strong>Over 12 months of follow-up, RCF showed bidirectional transitions with 0.535 reversion to NCF and 0.066 progression to CF. The transition probabilities of NCF progressing to RCF and CF were 0.232 and 0.055, respectively. MUOO demonstrated the highest probability of direct progression from NCF to CF (0.079). MHOO showed elevated short-term transition risk, with the higher probability from NCF to RCF (0.209) and RCF to CF (0.086) than MHNW. Compared with MHNW, MHOO increased the risk of transitioning from NCF to RCF (HR, 1.65, 95% CI, 1.00-2.73), while MUOO significantly amplified the risk from NCF to CF (HR, 3.15, 95% CI, 1.46-6.80).</p><p><strong>Conclusions: </strong>These preliminary findings emphasize the bidirectional nature of RCF transitions in Chinese older adults, highlighting its importance as an intervention window. Metabolic status demonstrates a strong association with obesity-related CF progression. MUOO correlates with irreversible decline, whereas MHOO is linked to accelerated early stage transitions. Tailored interventions targeting metabolic health in obese older adults may mitigate cognitive frailty risks and optimize outcomes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in adiposity indices over 10 years and risk of type 2 diabetes: The Whitehall II cohort study.","authors":"Cunrong Huang, Yuntao Chen, Annie Britton","doi":"10.1111/dom.16615","DOIUrl":"https://doi.org/10.1111/dom.16615","url":null,"abstract":"<p><strong>Aims: </strong>Common adiposity indices that are used to assess obesity include body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR). We aim to investigate change rates of the three indices in British middle-aged adults and compare effects of different adiposity indices' changes on incident type 2 diabetes.</p><p><strong>Materials and methods: </strong>Three repeated measures of BMI, WC and WHtR were collected over a decade (1991-2004) in 5666 participants without diabetes from the Whitehall II cohort study of British civil servants. Linear mixed-effects models were used to estimate standardised individual change rates of the three indices, and participants were then followed up for incident diabetes until 2023. We examined the prospective associations between change rates of the three indices and diabetes by Cox regression analysis.</p><p><strong>Results: </strong>The mean change rates for BMI, WC and WHtR were 0.04, 0.06 and 0.07 standard deviation (SD)/year, respectively. There were 633 incident diabetes cases after a median follow-up of 17.6 years. For every 1-SD increase per decade, WC change (HR: 3.01, 95% CI: 2.15-4.22) was associated with a higher diabetes risk than changes in WHtR (HR: 2.67, 95% CI: 2.00-3.55), and BMI (HR: 1.98, 95% CI: 1.53-2.56). No significant interactions were found between the change rates and either sex or age.</p><p><strong>Conclusions: </strong>The changes in WC and WHtR over a decade were associated with a higher risk of developing diabetes than the change in BMI in this British adult population. Routine monitoring of WC in general practice may provide more benefit than BMI management alone in preventing diabetes.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shifting obesity treatment paradigms: Trends of glucagon-like peptide-1 receptor agonists and bariatric surgery in the United States.","authors":"Ghadeer K Dawwas, Jason M Samuels, C Michael Stein","doi":"10.1111/dom.16600","DOIUrl":"https://doi.org/10.1111/dom.16600","url":null,"abstract":"","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}